Health
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
JERSEY CITY, N.J., April 15, 2026--VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2100,"height":315,"url":"https://media.zenfs.com/en/business-wire.com/7eb796df2e6a2a17fd7761201a488709"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SD0hcZXAiLRA6jjC89xWYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0NA--/https://media.zenfs.com/en/business-wire.com/7eb796df2e6a2a17fd7761201a488709","width":960,"height":144},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/3DD4XK1mAKVegZoyffyUrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNjA-/https://media.zenfs.com/en/business-wire.com/7eb796df2e6a2a17fd7761201a488709","width":1200,"height":180}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that is indicated across all severities in children aged 2 years and older with atopic dermatitis (AD)","length":323,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This recommendation reflects the proven efficacy, safety, and tolerability of VTAMA cream as a first-in-class, steroid-free, topical aryl hydrocarbon receptor (AhR) agonist for children and adolescents with AD","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AD, the most common form of eczema, impacts nearly 10 million children in the US","length":80,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":612,"olType":false},{"type":"text","content":"JERSEY CITY, N.J., April 15, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that VTAMA cream was granted a strong, evidence-based recommendation by the American Academy of Dermatology (AAD) in their 2026 guidelines for the management and treatment of atopic dermatitis (AD) in pediatric patients, published on April 7, 2026. The guidelines name VTAMA cream as the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence, that is indicated across all severities in children aged 2 years and older with AD. In the pivotal studies for VTAMA i...